Rare Disease Specialist Ultragenyx Takes $45MM Series A Round
This article was originally published in The Pink Sheet Daily
Executive Summary
Led by a BioMarin veteran, the year-old startup has already licensed five compounds, and is preparing to take one into the clinic.